Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for SHPG
181.00
+0.35 (0.19%)
After Hours: 185.00 +4.00 (2.21%)
Feb 22, 5:58PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 179.99 - 182.00
52 week 150.05 - 209.22
Open 180.12
Vol / Avg. 921,142.00/1.13M
Mkt cap 54.20B
P/E 64.87
Div/yield 0.14/0.44
EPS 2.79
Shares 912.20M
Beta 1.52
Inst. own 8%
Feb 13, 2017
Full Year 2016 Shire PLC Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 12.68% 5.37%
Operating margin 19.15% 8.45%
EBITD margin - 30.21%
Return on average assets 2.83% 1.46%
Return on average equity 6.50% 3.11%
Employees 5,548 -
CDP Score - 91 B

Address

Hampshire Intl Business Park, Chineham
BASINGSTOKE, RG24 8EP
United Kingdom - Map
+44-1256-894000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 58
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Executive Director
Age: 48
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
William Mordan General Counsel, Company Secretary
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 56
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 55
Bio & Compensation  - Reuters
Ian T. Clark Non-Executive Director
Age: 55
Bio & Compensation  - Reuters
Gail D. Fosler Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 61
Bio & Compensation  - Reuters